

**Astilbin from *Smilax glabra* Roxb. alleviates high-fat diet–induced
metabolic dysfunction**

**Tingwei Wang¹, Yongli Ye¹, Jian Ji¹, Shuang Zhang², Xingxing Yang¹, Jiayuan
Xu¹, Jiasheng Wang³, Zhiyuan Chen⁴, Bangen Xia⁵, Hongfang Shen⁵, Ruowei
Xia⁵, Wenqin Shi⁵, Xiulan Sun^{1*}**

¹School of Food Science, State Key Laboratory of Food Science and Technology, National Engineering Research Center for Functional Foods, School of Food Science Synergetic Innovation Center of Food Safety and Nutrition, Joint International Research Laboratory on Food Safety, Jiangnan University, Wuxi, Jiangsu 214122, China

² State Key Laboratory of Food Science and Technology, Jiangnan Analysis and Testing Center, Jiangnan University, Wuxi, Jiangsu 999078, China

³ Department of Environmental Health Science, College of Public Health, University of Georgia, Athens, GA, USA

⁴ College of Chinese Medicine, Macau University of Science and Technology, Macau, 999078, China

⁵ Ningbo Xiabang New Pharmaceutical Technology Co., Ltd., Ningbo, Zhejiang, 315000, China

*Corresponding authors: Xiulan Sun


Xiulan Sun: E-mail address: sxlzzz@jiangnan.edu.cn

MRM assay for astilbin


We used an ACQUITY UPLC TQD ultra performance liquid chromatography tandem triple quadrupole mass spectrometer (Waters Corporation, USA) set up an MRM assay for astilbin and tested the purchased standards. A liquid-phase method was used as follows: column: Waters BEH Shield RP18 column, $2.1 \times 100 \text{ mm}^2$ id, 5- μm film thickness (Waters, USA); mobile phases A and B: acetonitrile and 0.1% formic acid solution; flow rate: 0.3 mL/min; and column temperature: 45°C. The elution gradient was set as follows: 0-3 min, 5%-20% A; 3-5 min, 20%-40% A; 5-8 min, 40%-100% A, and the injection volume was 5 μL .

Mass spectrometry conditions: ionization mode: ESI-, capillary voltage: 3.0 k Volts, cone: 20/50 Volts, source block temperature: 100 °C, desolvation temperature: 400 °C, desolvation gas flow: 700 lit/hr, cone gas flow: 50 lit/hr, collision energy (eV) :6, detector voltage: 1800 Volts, ion pair: 449-151, 449-285,449-303. The chromatograms and MRM mode mass spectra are shown in Fig. s5


s1




a



b



c




d

Lipidlon	Fold change	P-value
TAG(56:7/FA20:5)	0.933016	0.004501
TAG(54:6/FA18:2)	0.842621	0.006688
TAG(55:2/FA18:2)	0.411757	0.00689
TAG(52:5/FA16:0)	0.973564	0.00833
TAG(56:6/FA20:3)	0.94084	0.008978
TAG(52:6/FA16:1)	0.986643	0.011012
TAG(56:6/FA22:6)	1.029228	0.013085
TAG(56:8/FA18:1)	1.196244	0.01385
TAG(55:1/FA18:1)	1.016715	0.021164
TAG(54:5/FA20:4)	0.945089	0.024522
TAG(50:5/FA18:3)	0.838938	0.02545
TAG(54:6/FA20:4)	0.939373	0.027399
TAG(54:6/FA16:0)	0.927384	0.029162
TAG(54:4/FA20:2)	0.904416	0.029762
TAG(54:6/FA22:6)	1.121496	0.041949
TAG(54:7/FA22:6)	1.109265	0.042664
TAG(55:7/FA22:6)	0.958775	0.046767
TAG(56:8/FA16:1)	0.977744	0.047557
TAG(49:0/FA16:0)	1.057419	0.048298
TAG(56:4/FA18:1)	0.846389	0.049217


e

Lipidlon	Fold Change	P-value
PE(P-16:0/16:0)	0.22312	9.72E-06
PE(P-16:0/16:1)	0.38797	0.002198
PE(P-14:0/18:1)	0.42331	0.003648
LPG(20:4)	0.42832	0.003905
PS(16:0/16:1)	0.46801	0.014554
PE(O-16:0/20:4)	0.5072	0.00696
LPG(22:4)	0.52344	0.001223
PE(P-18:1/20:3)	0.53077	2.70E-05
PE(14:0/22:5)	0.56049	0.030059
PE(O-16:0/22:6)	0.56234	0.000264
PS(16:0/16:0)	0.5759	0.00025
PC(18:0/22:5)	1.812	7.74E-06
PC(18:1/20:5)	1.8245	0.004986
PE(O-18:0/18:3)	1.8441	0.006599
LPC(20:5)	1.8971	0.000547
PC(16:0/22:5)	1.9278	3.60E-06
PC(18:2/20:5)	2.713	1.00E-04
PC(18:0/20:0)	3.7944	1.89E-05
PC(20:0/20:5)	4.0803	0.001748
PS(20:0/20:5)	26.588	0.023116


a





b



c



s4




c

Number	Metabolites	Fold Change	P-value	VIP
1	L-Proline	0.352	0.017	1.458
2	D-2-Aminobutyric acid	0.409	0.013	1.434
3	N-Acetylmethionine	0.431	<0.001	1.952
4	beta-Alanine	0.437	<0.001	2.133
5	4-Aminobutanoate	0.451	<0.001	1.872
6	4-Chloropyridine-2,6-Dicarboxylic Acid	0.506	0.046	1.043
7	Tryptamine	0.564	0.029	1.366
8	D-Arabitol	0.566	0.003	1.614
9	Glutamate	0.566	0.024	1.406
10	L-Ornithine hydrochloride	0.572	0.037	1.260
11	Oleamide	0.576	0.018	1.383
12	Xanthine	0.580	0.001	1.831
13	N-Acetyl-D-glucosamine	0.587	0.018	1.353
14	L-Asparagine	0.605	0.024	1.332
15	L-Cysteine	0.619	0.016	1.512
16	sn-Glycerol-1-phosphate	0.630	0.019	1.294
17	1-Monopalmitin	0.657	0.002	1.653
18	Pentitol	0.666	<0.001	1.835
19	D-Panose	1.543	0.037	1.445
20	Adenine	1.597	0.011	1.561
21	Lactitol	1.616	0.015	1.611
22	Trehalose	1.647	0.011	1.639
23	Adenosine	1.726	0.025	1.522
24	beta-Sitosterol	1.754	0.024	1.372
25	Lactobionic acid	2.089	0.011	1.379
26	Arabinose 5-phosphate	4.211	<0.001	1.869
27	Adenosine 5-Monophosphate	5.926	<0.001	2.233

s5

a



b




Figure Captions

Figure s1. Development of astilbin intervention models.

Figure s2. Effects of astilbin consumption on HFD-induced liver lipid metabolism disorders. **(a)** Log₂ fold changes in lipid species in the HFD + Astilbin versus HFD groups and the corresponding significance values displayed as $-\log_{10}(P \text{ value})$. Each dot represents a lipid species, and the dot size indicates significance. **(b)** Intensity fold change of sphingolipids. **(c)** Levels of SFA, MUFA, and PUFA in the liver TG of mice in the HFD + Astilbin and HFD groups. **(d)** Top 20 TGs according to the P value, detected in livers of mice in the HFD + astilbin and HFD groups ($n = 8$). **(e)** Top 20 glycerophospholipids according to the P value, detected in livers of mice in the HFD + Astilbin and HFD groups ($n = 8$).

Figure s3. Effects of astilbin consumption on microbiota composition of HFD-fed mice. **(a)** Bar graph of bacterial abundance at the genus level. **(b)** Astilbin consumption induced altered flora in HFD mice. **(c)** LDA-based analysis of KEGG level 3 in the HFD + Astilbin versus HFD groups significantly altered the pathway.

Figure s4. Effect of astilbin on liver metabolism in HFD-fed mice. **(a)** PCA analysis of major sources of metabolite variability. **(b)** Validation plot for discriminating HFD + Astilbin and HFD groups. **(c)** Statistical analysis of differential metabolites in the liver to distinguish the HFD + Astilbin group from the HFD group.

Figure s5. Characterization of astilbin. **(a)** Chromatogram and ion pair information. **(b)** MRM mode mass spectra.

